Has the new TNM classification for colorectal cancer improved care?

被引：167

作者：

Nagtegaal, Iris D. ^{[1
]}

Quirke, Phil ^{[2
]}

Schmoll, Hans-Joachim ^{[3
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6500 HB Nijmegen, Netherlands

[2] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Mol Med, Leeds LS9 7TF, W Yorkshire, England

[3] Univ Hosp Halle, Dept Oncol, D-06120 Halle, Germany

来源：

NATURE REVIEWS CLINICAL ONCOLOGY | 2012年 / 9卷 / 02期

关键词：

AMERICAN-JOINT-COMMITTEE; EVIDENCE-BASED MEDICINE; ADVANCED RECTAL-CANCER; TUMOR DEPOSITS; STAGING SYSTEM; SET STANDARDS; 7TH EDITION; TIME; CATEGORIZATION; RADIOTHERAPY;

D O I：

10.1038/nrclinonc.2011.157

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

In 2009, the Union for International Cancer Control issued the seventh edition of the well-used T (tumor), N (node), and M (metastasis) classification guidelines. There has been a continual refinement of the staging for colorectal cancer since this system for assessing tumor stage was initially adopted and it has been used to guide treatment decisions for over 50 years. However, the outcome after therapy for patients with colorectal cancer is very variable, even when patients are assigned to the same TNM category. This article assesses the changes that have been made since the sixth edition and discusses whether they are, in fact, informative improvements for a practicing clinician. Nagtegaal, I. D. etal. Nat. Rev. Clin. Oncol. 9, 119-123(2012): published online 18 October 2011; doi:10.1038/nrclinonc.2011.157

引用

页码：119 / 123

页数：5

共 37 条

[1]

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[2]

Allen DC, 1999, ULSTER MED J, V68, P17

[3]

[Anonymous], ANN ONCOL IN PRESS

[4]

[Anonymous], VIRT PATH U LEEDS

[5]

[Anonymous], 1997, J CLIN PATHOL

[6]

THE PROGNOSTIC SIGNIFICANCE OF DIRECT EXTENSION OF CARCINOMA OF THE COLON AND RECTUM [J].

ASTLER, VB ;

COLLER, FA .

ANNALS OF SURGERY, 1954, 139 (06) :846-852

[7]

American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].

Benson, AB ;

Schrag, D ;

Somerfield, MR ;

Cohen, AM ;

Figueredo, AT ;

Flynn, PJ ;

Krzyzanowska, MK ;

Maroun, J ;

McAllister, P ;

Van Cutsem, E ;

Brouwers, M ;

Charette, M ;

Haller, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419

[8]

Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer [J].

Chan, I ;

Brown, G ;

Cunningham, D ;

Tait, D ;

Wotherspoon, A ;

Norman, AR ;

Tebbutt, N ;

Hill, M ;

Ross, PJ ;

Massey, A ;

Oates, J .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (04) :668-674

[9]

Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006 [J].

Elferink, M. A. G. ;

van Steenbergen, L. N. ;

Krijnen, P. ;

Lemmens, V. E. P. P. ;

Rutten, H. J. ;

Marijnen, C. A. M. ;

Nagtegaal, I. D. ;

Karim-Kos, H. E. ;

de Vries, E. ;

Siesling, S. .

EUROPEAN JOURNAL OF CANCER, 2010, 46 (08) :1421-1429

[10]

Neoadjuvant Therapy in Rectal Cancer [J].

Fleming, Fergal J. ;

Pahlman, Lars ;

Monson, John R. T. .

DISEASES OF THE COLON & RECTUM, 2011, 54 (07) :901-912

← 1 2 3 4 →